Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome

Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome

Allogeneic hematopoietic stem cell transplantation (HSCT) represents the only curative treatment for patients with myelodysplastic syndrome (MDS), but involves non-negligible morbidity and mortality. Registry studies have shown that advanced disease stage at transplantation is associated with inferi...

Full description

Bibliographic Details
Main Authors: Alessandrino, Emilio Paolo, Porta, Matteo G Della, Malcovati, Luca, Jackson, Christopher H, Pascutto, Cristiana, Bacigalupo, Andrea, Teresa van Lint, Maria, Falda, Michele, Bernardi, Massimo, Onida, Francesco, Guidi, Stefano, Iori, Anna Paola, Cerretti, Raffaella, Marenco, Paola, Pioltelli, Pietro, Angelucci, Emanuele, Oneto, Rosi, Ripamonti, Francesco, Rambaldi, Alessandro, Bosi, Alberto, Cazzola, Mario
Format: Online
Language:English
Published: Blackwell Publishing Ltd 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3736162/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3736162/

Similar Items